Guest guest Posted April 1, 2011 Report Share Posted April 1, 2011 HIVandHepatitis.com e newsletter for April 1, 2011e-Newsletter for Friday, April 1, 2011 Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment SUMMARY The REALIZE study showed that adding telaprevir to standard hepatitis C therapy increased sustained response rates for people with previous unsuccessful treatment attempts, researchers reported this week at EASL 2011. Boceprevir Improves Response to Interferon-Based HCV Therapy SUMMARY The HCV protease inhibitor boceprevir improved sustained response rates when combined with pegylated interferon plus ribavirin in both previously untreated patients and prior non-responders, according to findings from 2 studies published in the March 31 New England Journal of Medicine. Boceprevir Helps Hepatitis C Patients with Cirrhosis SUMMARY Chronic hepatitis C patients with advanced liver fibrosis or cirrhosis were more likely to achieve a cure when they added boceprevir to standard therapy, according to a report this week at EASL 2011. 4-Drug Combo with Telaprevir and VX-222 Clears HCV at 12 Weeks SUMMARY 90% of previously untreated genotype 1 chronic hepatitis C patients treated with telaprevir plus VX-222 plus pegylated interferon and ribavirin achieved undetectable viral load at week 12, researchers reported at EASL 2011. Statin Boosts Response to Pegylated Interferon/Ribavirin SUMMARY Fluvastatin, a drug typically used to manage high cholesterol, improved early and sustained virological response rates among chronic hepatitis C patients taking pegylated interferon plus ribavirin, according to a report at EASL 2011. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 1, 2011 Report Share Posted April 1, 2011 HIVandHepatitis.com e newsletter for April 1, 2011e-Newsletter for Friday, April 1, 2011 Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment SUMMARY The REALIZE study showed that adding telaprevir to standard hepatitis C therapy increased sustained response rates for people with previous unsuccessful treatment attempts, researchers reported this week at EASL 2011. Boceprevir Improves Response to Interferon-Based HCV Therapy SUMMARY The HCV protease inhibitor boceprevir improved sustained response rates when combined with pegylated interferon plus ribavirin in both previously untreated patients and prior non-responders, according to findings from 2 studies published in the March 31 New England Journal of Medicine. Boceprevir Helps Hepatitis C Patients with Cirrhosis SUMMARY Chronic hepatitis C patients with advanced liver fibrosis or cirrhosis were more likely to achieve a cure when they added boceprevir to standard therapy, according to a report this week at EASL 2011. 4-Drug Combo with Telaprevir and VX-222 Clears HCV at 12 Weeks SUMMARY 90% of previously untreated genotype 1 chronic hepatitis C patients treated with telaprevir plus VX-222 plus pegylated interferon and ribavirin achieved undetectable viral load at week 12, researchers reported at EASL 2011. Statin Boosts Response to Pegylated Interferon/Ribavirin SUMMARY Fluvastatin, a drug typically used to manage high cholesterol, improved early and sustained virological response rates among chronic hepatitis C patients taking pegylated interferon plus ribavirin, according to a report at EASL 2011. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.